- Home
- IPHA vs VOXR Comparison
IPHA vs VOXR Comparison
Compare IPHA & VOXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPHA
- VOXR
- Stock Information
- Founded
- IPHA 1999
- VOXR 2014
- Country
- IPHA France
- VOXR United States
- Employees
- IPHA N/A
- VOXR N/A
- Industry
- IPHA Biotechnology: Pharmaceutical Preparations
- VOXR Precious Metals
- Sector
- IPHA Health Care
- VOXR Basic Materials
- Exchange
- IPHA Nasdaq
- VOXR Nasdaq
- Market Cap
- IPHA 160.1M
- VOXR 187.3M
- IPO Year
- IPHA 2019
- VOXR N/A
- Fundamental
- Price
- IPHA $2.05
- VOXR $3.47
- Analyst Decision
- IPHA Strong Buy
- VOXR
- Analyst Count
- IPHA 1
- VOXR 0
- Target Price
- IPHA $11.00
- VOXR N/A
- AVG Volume (30 Days)
- IPHA 14.6K
- VOXR 292.8K
- Earning Date
- IPHA 09-17-2025
- VOXR 11-05-2025
- Dividend Yield
- IPHA N/A
- VOXR 1.42%
- EPS Growth
- IPHA N/A
- VOXR N/A
- EPS
- IPHA N/A
- VOXR N/A
- Revenue
- IPHA $14,839,695.00
- VOXR $10,771,473.00
- Revenue This Year
- IPHA $350.96
- VOXR $22.51
- Revenue Next Year
- IPHA $32.92
- VOXR $10.60
- P/E Ratio
- IPHA N/A
- VOXR N/A
- Revenue Growth
- IPHA N/A
- VOXR N/A
- 52 Week Low
- IPHA $1.29
- VOXR $2.21
- 52 Week High
- IPHA $3.51
- VOXR $3.79
- Technical
- Relative Strength Index (RSI)
- IPHA 46.87
- VOXR 49.85
- Support Level
- IPHA $1.93
- VOXR $3.45
- Resistance Level
- IPHA $2.19
- VOXR $3.70
- Average True Range (ATR)
- IPHA 0.11
- VOXR 0.13
- MACD
- IPHA -0.01
- VOXR -0.01
- Stochastic Oscillator
- IPHA 49.66
- VOXR 21.62
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
About VOXR Vox Royalty Corp.
Vox Royalty Corp is a returns-focused mining royalty company with a portfolio of royalties and streams spanning eight jurisdictions. It has built intellectual property, a technically focused transactional team, and a sourcing network which has allowed Vox to target the highest returns on royalty acquisitions in the mining royalty sector. The company geographically operates Australia, Nigeria, USA, and Brazil.